Skip to content
Excepgen logo

Excepgen

Excepgen is a YC Winter 2019 (W19) company. Based in San Francisco, CA, USA. Team of 3.

  • Biotech

About Excepgen

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Excepgen develops RNA-based vaccines with improved tolerability by targeting the cellular response to nucleic acids rather than their chemistry or delivery. Its RNAx platform encodes a protein that suppresses the overactive innate immune response triggered by mRNA vaccines and lipid nanoparticles, reducing side effects without sacrificing efficacy. The work addresses a biological limitation that existing capping, delivery, and modified-nucleoside approaches leave unsolved.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Francisco, CA, USA
Team size
3
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works